Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 520 participants.

Also called NCT07758023

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 520 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07758023
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07758023. Randomized; no masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2030-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
Acronym
ACHILLES-HF
Condition
Mitral Regurgitation Functional
Intervention (Device)
M-TEER
Intervention (Other)
Standardized GDMT Up-Titration
Lead sponsor
University Medical Center Mainz (class: other)
Collaborator
Abbott (class: industry)

Record details

Record id
cardio:ct-nct07758023
Content hash
c42748ae93c9118b8399fa903e355ca33608821878c1c5c69aa8bbcf49901445